ALVAC-HIV as a prophylactic and therapeutic vaccine: highlights from over a decade of clinical trials

Author： Costiniuk Cecilia T Angel Jonathan B

ISSN： 1746-0794

Source： Future Virology, Vol.6, Iss.12, 2011-12, pp. : 1481-1492

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The ABC of HIV Clinical Trials

By Hill Andrew

Pharmaceutical Medicine, Vol. 23, Iss. 4, 2009-08 ,pp. : 201-211

Adis International

Access to resources Recommend Favorite

Vaccine Clinical Trials – A Statistical Primer

By Mehrotra D. V.

Journal of Biopharmaceutical Statistics, Vol. 16, Iss. 4, 2006-07 ,pp. : 403-414

Taylor & Francis Ltd

Access to resources Recommend Favorite

Therapeutic Targeting of TRPV1 by Resiniferatoxin, from Preclinical Studies to Clinical Trials

Current Topics in Medicinal Chemistry, Vol. 11, Iss. 17, 2011-09 ,pp. : 2159-2170

Bentham Science Publishers

Access to resources Recommend Favorite

Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications

By Testa James S Philip Ramila

Future Virology, Vol. 7, Iss. 11, 2012-11 ,pp. : 1077-1088

Future Medicine

Access to resources Recommend Favorite

Prophylactic Vaccine Strategies and the Potential of Therapeutic Vaccines Against Herpes Simplex Virus

Current Pharmaceutical Design, Vol. 13, Iss. 19, 2007-07 ,pp. : 1975-1988

Bentham Science Publishers

Access to resources Recommend Favorite